The Priority Review

Clinical trials Brief

Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis

The study, led by Jiankuan (Suzhou) Biotechnology Company Limited, plans to enroll 590 participants and begin on October 15, 2026. It is to evaluate different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs.

Primary source

ClinicalTrials.gov registry record, October 2, 2026

A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis

Read the source: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation